Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry

By Öner Tulum & William Lazonick ◊ There are widespread claims that a productivity crisis afflicts the U.S. pharmaceutical industry despite the fact that the U.S. institutional environment provides unique advantages for drug R&D. We argue that the explanation for this productivity paradox is the “financialization” of the U.S. pharmaceutical industry. Driven by shareholder-value ideology, the U.S. pharmaceutical industry has adopted a highly financialized business model…

U.S. Sen. Baldwin: Reintroduces legislation to rein in stock buybacks and give workers a voice on corporate boards

By Sen. Tammy Baldwin, press release “Today, U.S. Senator Tammy Baldwin reintroduced legislation to rein in corporate stock buybacks and empower workers to have a say in how their company’s profits are spent. The Reward Work Act would ban open-market stock buybacks…